FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1903109303> ?p ?o ?g. }

• W1903109303 endingPage "6021" @default.
• W1903109303 startingPage "6021" @default.
• W1903109303 abstract "6021 Background: To evaluate the effectiveness of topically applied human recombinant epidermal growth factor (rhEGF) in the reduction of oral mucositis induced by radiotherapy (or concurrent chemoradiotherapy) in patients with head and neck cancer. Methods: Patients with head and neck cancer receiving external radiotherapy (RT) to the oral cavity or soft palate with conventional fractionation (2 Gy/fraction, 5 fractions weekly, minimum 25 fractions) were entered into a study. Patients were assigned to a placebo group or to one of three EGF-treatment groups (10 μg/ml, 50 μg/ml, or 100 μg/ml). EGF was delivered in a spray twice daily to the whole oral cavity, beginning at the start of RT and continuing through 5 weeks of RT. The primary endpoint examined was mucositis, and the grade of mucositis was evaluated weekly by physicians using the Radiation Therapy Oncology Group (RTOG) scale for acute mucosal morbidity. Responders to EGF were defined as having a RTOG grade 1 score or lower during RT through week 4–5 and don't maintain RTOG grade 2 for week 4–5. Secondary endpoints were WHO oral toxicity scale grade, patient weight, pain score, opioid analgesia use, and time to develop mucositis. Results: Of the 113 patients from six institutions enrolled, 28 were placed in the placebo group, 29 received EGF at 10 μg/ml, 29 at 50 μg/ml, and 27 at 100 μg/ml. Thirteen patients (11.5%) were excluded from further analysis. Forty had nasopharyngeal carcinomas, and 37 had cancers of the oropharynx, 23 of the oral cavity, and 23 in other locations. Compared to placebo, EGF significantly reduced the incidence of severe oral mucositis for the primary endpoint (63% response with EGF at 50 μg/ml vs. 34% response in the control group; p = 0.0227). However, no differences in any secondary endpoints were found between groups. Conclusions: RhEGF oral spray during radiotherapy (or concurrent chemoradiotherapy) is safe and has therapeutic activity against oral mucositis in patients with head and neck cancer. Further phase III study is needed to confirm these results. No significant financial relationships to disclose." @default.
• W1903109303 created "2016-06-24" @default.
• W1903109303 creator A5013165857 @default.
• W1903109303 creator A5038454077 @default.
• W1903109303 creator A5059384917 @default.
• W1903109303 creator A5066272464 @default.
• W1903109303 creator A5069035606 @default.
• W1903109303 creator A5069833457 @default.
• W1903109303 creator A5074803385 @default.
• W1903109303 creator A5087968595 @default.
• W1903109303 date "2008-05-20" @default.
• W1903109303 modified "2023-09-26" @default.
• W1903109303 title "The therapeutic effect of recombinant human epidermal growth factor (rhEGF) on mucositis in patients with head and neck cancer undergoing radiotherapy with or without chemotherapy: a double-blind placebo-controlled prospective phase II multi-institutional study" @default.
• W1903109303 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.6021" @default.
• W1903109303 hasPublicationYear "2008" @default.
• W1903109303 type Work @default.
• W1903109303 sameAs 1903109303 @default.
• W1903109303 citedByCount "3" @default.
• W1903109303 countsByYear W19031093032017 @default.
• W1903109303 crossrefType "journal-article" @default.
• W1903109303 hasAuthorship W1903109303A5013165857 @default.
• W1903109303 hasAuthorship W1903109303A5038454077 @default.
• W1903109303 hasAuthorship W1903109303A5059384917 @default.
• W1903109303 hasAuthorship W1903109303A5066272464 @default.
• W1903109303 hasAuthorship W1903109303A5069035606 @default.
• W1903109303 hasAuthorship W1903109303A5069833457 @default.
• W1903109303 hasAuthorship W1903109303A5074803385 @default.
• W1903109303 hasAuthorship W1903109303A5087968595 @default.
• W1903109303 hasConcept C121608353 @default.
• W1903109303 hasConcept C126322002 @default.
• W1903109303 hasConcept C141071460 @default.
• W1903109303 hasConcept C142724271 @default.
• W1903109303 hasConcept C204787440 @default.
• W1903109303 hasConcept C27081682 @default.
• W1903109303 hasConcept C2776530083 @default.
• W1903109303 hasConcept C2776694085 @default.
• W1903109303 hasConcept C2778424827 @default.
• W1903109303 hasConcept C2778496288 @default.
• W1903109303 hasConcept C31760486 @default.
• W1903109303 hasConcept C509974204 @default.
• W1903109303 hasConcept C71924100 @default.
• W1903109303 hasConcept C90924648 @default.
• W1903109303 hasConceptScore W1903109303C121608353 @default.
• W1903109303 hasConceptScore W1903109303C126322002 @default.
• W1903109303 hasConceptScore W1903109303C141071460 @default.
• W1903109303 hasConceptScore W1903109303C142724271 @default.
• W1903109303 hasConceptScore W1903109303C204787440 @default.
• W1903109303 hasConceptScore W1903109303C27081682 @default.
• W1903109303 hasConceptScore W1903109303C2776530083 @default.
• W1903109303 hasConceptScore W1903109303C2776694085 @default.
• W1903109303 hasConceptScore W1903109303C2778424827 @default.
• W1903109303 hasConceptScore W1903109303C2778496288 @default.
• W1903109303 hasConceptScore W1903109303C31760486 @default.
• W1903109303 hasConceptScore W1903109303C509974204 @default.
• W1903109303 hasConceptScore W1903109303C71924100 @default.
• W1903109303 hasConceptScore W1903109303C90924648 @default.
• W1903109303 hasIssue "15_suppl" @default.
• W1903109303 hasLocation W19031093031 @default.
• W1903109303 hasOpenAccess W1903109303 @default.
• W1903109303 hasPrimaryLocation W19031093031 @default.
• W1903109303 hasRelatedWork W1821727971 @default.
• W1903109303 hasRelatedWork W1978232913 @default.
• W1903109303 hasRelatedWork W2102647385 @default.
• W1903109303 hasRelatedWork W2110923848 @default.
• W1903109303 hasRelatedWork W2132010426 @default.
• W1903109303 hasRelatedWork W2233758049 @default.
• W1903109303 hasRelatedWork W2977309342 @default.
• W1903109303 hasRelatedWork W2997709950 @default.
• W1903109303 hasRelatedWork W3122076712 @default.
• W1903109303 hasRelatedWork W2185375481 @default.
• W1903109303 hasVolume "26" @default.
• W1903109303 isParatext "false" @default.
• W1903109303 isRetracted "false" @default.
• W1903109303 magId "1903109303" @default.
• W1903109303 workType "article" @default.